Gastroparesis Drugs Market Size | Global Analysis [2033]

Gastroparesis Drugs Market Overview

The Gastroparesis Drugs Market size was valued at USD 6435.65 million in 2024 and is expected to reach USD 9378.93 million by 2033, growing at a CAGR of 4.3% from 2025 to 2033.

The global gastroparesis drugs market is witnessing significant growth, driven by the increasing prevalence of diabetes and advancements in drug development. In 2023, the market was valued at approximately USD 4.6 billion, with diabetic gastroparesis accounting for 44.6% of the market share. The rising number of diabetic patients, particularly those with type 2 diabetes, has led to an increased incidence of gastroparesis, necessitating effective treatment options. Prokinetic agents dominate the market, holding a 40% share, followed by antiemetic agents at 30%. The demand for over-the-counter (OTC) drugs is also notable, with this segment contributing 64.1% to the market in 2023, reflecting patient preference for accessible and convenient treatment options.

Key Findings

Top Driver Reason: Rising prevalence of diabetes leading to increased cases of diabetic gastroparesis.

Top Country/Region: North America, accounting for 45% of the market share in 2023.

Top Segment: Diabetic gastroparesis, representing 44.6% of the market in 2023.

Gastroparesis Drugs Market Trends

The gastroparesis drugs market is characterized by several emerging trends that are shaping its growth trajectory. One significant trend is the increasing investment in research and development (R&D) activities aimed at introducing novel therapeutic options. For instance, Processa Pharmaceuticals initiated a Phase 2a clinical trial for PCS12852, targeting moderate to severe gastroparesis. Similarly, CinDome Pharma's deudomperidone (CIN-102) entered Phase II trials in 2024, backed by a USD 40 million Series B financing round.

Another trend is the growing preference for oral medications, which are expected to reach a market size of USD 4.8 billion by 2032. Oral drugs offer convenience and non-invasiveness, aligning with patient preferences. Additionally, the OTC drugs segment dominated the market with a 64.1% share in 2023, driven by the accessibility and immediate relief these drugs provide. The Asia-Pacific region is emerging as a significant market, with a projected growth rate of 5.5% from 2024 to 2029. Factors contributing to this growth include a rising diabetic population, increased surgical procedures, and improved healthcare infrastructure. Countries like India and China are at the forefront, with India having approximately 74.9 million diabetic individuals aged 20-79 in 2021, expected to reach 124.9 million by 2045.

Gastroparesis Drugs Market Dynamics

DRIVER

Rising demand for pharmaceuticals

The increasing prevalence of diabetes is a primary driver of the gastroparesis drugs market. In 2021, approximately 537 million adults were living with diabetes, a number projected to rise to 643 million by 2030. Diabetic gastroparesis, a complication of diabetes, affects about 30% of type 1 and 12-15% of type 2 diabetes patients. This growing patient pool necessitates effective treatment options, thereby propelling the demand for gastroparesis drugs.

RESTRAINT

Demand for refurbished equipment

The high cost associated with the development and treatment of new gastroparesis drugs poses a significant restraint. Pharmaceutical companies face pressure to produce novel therapies while managing costs effectively, often resulting in prolonged timelines for bringing new therapies to market. This financial burden can hinder innovation and accessibility, particularly in developing regions with limited healthcare resources.

OPPORTUNITY

Growth in personalized medicines

The trend towards personalized medicine offers substantial opportunities in the gastroparesis drugs market. Tailoring treatments to individual patient profiles based on genetic or biological markers can enhance therapeutic efficacy and minimize adverse effects. This approach is particularly crucial for gastroparesis patients, who often deal with multiple health issues, and provides new avenues for growth and innovation within the market.

CHALLENGE

Rising costs and expenditures

Despite promising growth, the gastroparesis drugs market faces challenges such as the variability of symptoms among patients, which complicates clinical trials and treatment protocols. Additionally, the lack of robust clinical data demonstrating the efficacy and safety of existing therapies can hamper market penetration. These challenges underscore the need for continued research and development to establish standardized treatment protocols and improve patient outcomes.

Gastroparesis Drugs Market Segmentation

The gastroparesis drugs market is segmented by type and application, each with distinct characteristics and growth patterns.

By Type

Diabetic Gastroparesis: This segment held the largest market share in 2023, accounting for 44.6%. The high prevalence of diabetes worldwide, particularly type 2 diabetes, contributes to the dominance of this segment. Approximately 537 million adults were living with diabetes in 2021, a number projected to rise to 643 million by 2030, leading to an increased incidence of diabetic gastroparesis.
Idiopathic Gastroparesis: Representing 25% of the market, idiopathic gastroparesis is projected to grow at a rate of 9% during the forecast period. Advances in diagnostic techniques and treatment options are driving this growth, as more cases are identified and managed effectively.

By Application

Prokinetic Agents: Dominating the market with a 40% share, prokinetic agents enhance gastric motility, addressing the underlying issue of delayed gastric emptying in gastroparesis patients. Their effectiveness in symptom management makes them a cornerstone in treatment protocols.
Antiemetic Agents: Holding a 30% market share, antiemetic agents are essential in managing nausea and vomiting associated with gastroparesis. Their role in improving patient quality of life contributes to their significant market presence.
Others: This category includes botulinum toxin injections and other emerging therapies, accounting for 10% of the market. The fastest-growing sub-segment is botulinum toxin injections, expanding at a rate of 12%, driven by increasing off-label use and clinical success.

Gastroparesis Drugs Market Regional Outlook

The gastroparesis drugs market exhibits varying dynamics across different regions, influenced by factors such as disease prevalence, healthcare infrastructure, and regulatory environments.

North America

In 2023, North America dominated the market, accounting for 45% of the global share. The high prevalence of diabetes, advanced healthcare infrastructure, and increased awareness contribute to this dominance. The United States, in particular, has a significant diabetic population, with approximately 37.3 million people diagnosed in 2021. The region also benefits from robust R&D activities and the presence of key market players.

Europe

Europe held a 30% market share in 2023, with countries like Germany, the UK, and France leading in terms of market size. The region's growth is driven by a rising geriatric population, increased healthcare spending, and advancements in drug development. Europe also sees a growing trend towards personalized medicine, enhancing treatment efficacy for gastroparesis patients.

Asia-Pacific

The Asia-Pacific region is the fastest-growing market, with a projected growth rate of 5.5% from 2024 to 2029. In 2024, the market size was approximately USD 1.16 billion, expected to reach USD 1.52 billion by 2029. Factors such as a rising diabetic population, increased surgical procedures, and improved healthcare infrastructure contribute to this growth. Countries like India and China are at the forefront, with India having approximately 74.9 million diabetic individuals aged 20-79 in 2021, expected to reach 124.9 million by 2045.

Middle East & Africa

This region accounted for 5% of the market share in 2023. While the market is relatively small, it is poised for growth due to increasing awareness of gastroparesis, improving healthcare infrastructure, and rising prevalence of diabetes. Efforts to enhance diagnostic capabilities and access to treatment are expected to drive market expansion in the coming years.

List of Top Gastroparesis Drugs Companies

Sumitomo
Cadila Pharmaceuticals
Sanofi
Teva
Johnson & Johnson
Pfizer
Kyowa Kirin Pharmaceuticals
Hanmi Pharm
Ani Pharmaceuticals

Top Two Companies with Highest Market Share

Pfizer: As a leading pharmaceutical company, Pfizer has a significant presence in the gastroparesis drugs market, leveraging its extensive R&D capabilities and global reach to develop and distribute effective treatments.
Johnson & Johnson: With a diverse portfolio and strong focus on innovation, Johnson & Johnson holds a substantial share in the market, offering a range of therapies that address various aspects of gastroparesis management.

Investment Analysis and Opportunities

The gastroparesis drugs market presents numerous investment opportunities, driven by the increasing prevalence of the condition and the demand for effective treatments. In 2024, CinDome Pharma secured USD 40 million in a Series B financing round to advance the development of deudomperidone (CIN-102), a promising treatment for chronic gastroparesis. Similarly, Processa Pharmaceuticals initiated a Phase 2a clinical trial for PCS12852, targeting moderate to severe gastroparesis. Investments are also flowing into the development of novel drug delivery systems, such as extended-release formulations and nasal sprays, enhancing patient compliance and treatment efficacy. For instance, Evoke Pharma's GIMOTI, a nasal spray formulation of metoclopramide, received FDA approval in 2020, offering a non-invasive treatment option for diabetic gastroparesis.

Emerging markets, particularly in the Asia-Pacific region, offer lucrative investment prospects due to the rising diabetic population and improving healthcare infrastructure. Companies like Abbott are expanding their R&D teams in countries like India and China to tap into these growing markets. Furthermore, the trend towards personalized medicine is attracting investments aimed at developing treatments tailored to individual patient profiles. This approach enhances therapeutic efficacy and minimizes adverse effects, aligning with the broader movement towards precision healthcare.

New Product Development

Innovation is at the forefront of the gastroparesis drugs market, with several new products in development aimed at addressing unmet medical needs. In December 2023, Vanda Pharmaceuticals announced that the FDA accepted the filing of its New Drug Application for tradipitant, targeting gastroparesis symptoms. Tradipitant is a neurokinin-1 receptor antagonist that has shown promise in clinical trials for reducing nausea and vomiting. Relamorelin, a synthetic peptide and ghrelin receptor agonist, is another novel therapy under development by Allergan for diabetic gastroparesis. It has demonstrated improved gastric emptying and symptom relief in clinical studies, with the FDA granting it Fast Track designation. Deudomperidone (CIN-102), developed by CinDome Pharma, is a deuterated form of domperidone currently in Phase II clinical trials. It has shown enhanced safety and efficacy profiles in preliminary studies, particularly for chronic gastroparesis, and is poised to become a game-changer if approved. Its development is backed by a USD 40 million Series B investment, reflecting high investor confidence. Evoke Pharma’s GIMOTI, a metoclopramide nasal spray, continues to gain traction in the market. It is the first and only nasal formulation of its kind, offering an alternative for patients unable to tolerate oral medications due to vomiting. Since its FDA approval in 2020, GIMOTI has demonstrated consistent year-on-year growth, with prescription volumes increasing by 15% in 2023 alone. Several companies are also exploring gene therapy and microbiota-based treatments to address gastroparesis at the root level. These next-generation therapies aim to restore normal gastric function rather than merely treating symptoms. The integration of artificial intelligence in drug development and patient stratification is also accelerating innovation, with predictive analytics improving the success rates of clinical trials. The pipeline is robust, with over 30 active clinical trials worldwide focusing on gastroparesis-related drug development as of Q1 2024. This dynamic innovation landscape underscores the market’s potential for transformative therapies and positions it as an exciting space for investors and researchers alike.

Five Recent Developments

CinDome Pharma’s Phase II Trials of CIN-102: In Q2 2024, CinDome Pharma began Phase II trials for deudomperidone (CIN-102), a novel formulation designed to reduce nausea and vomiting in chronic gastroparesis patients. The trial involves over 150 patients across the U.S., with preliminary results showing a 20% improvement in gastric motility compared to placebo.
FDA Acceptance of Tradipitant NDA: In December 2023, the FDA accepted Vanda Pharmaceuticals’ New Drug Application (NDA) for tradipitant. Clinical studies demonstrated a 45% reduction in nausea frequency and 33% improvement in patient-reported symptom scores after eight weeks of treatment.
Evoke Pharma's GIMOTI Expansion: Evoke Pharma expanded GIMOTI distribution to over 1,000 additional pharmacies in North America in Q3 2023. The nasal spray showed a 15% year-over-year increase in prescriptions, particularly among diabetic patients experiencing oral medication intolerance.
Processa Pharmaceuticals Initiates PCS12852 Trials: In January 2024, Processa Pharmaceuticals launched a Phase 2a clinical trial for PCS12852. The trial includes 80 participants and focuses on moderate-to-severe cases of gastroparesis, with interim results expected by Q4 2024.
Kyowa Kirin’s Partnership with Hanmi Pharm: In late 2023, Kyowa Kirin and Hanmi Pharm entered into a partnership to co-develop and commercialize a novel prokinetic agent in the Asia-Pacific region. The partnership aims to complete Phase I trials in Korea by the end of 2024 and targets a market launch by 2026.

Report Coverage of Gastroparesis Drugs Market

This report offers a comprehensive and detailed analysis of the gastroparesis drugs market, covering a wide spectrum of data points essential for stakeholders across the healthcare and pharmaceutical industries. The study examines current and projected market sizes, segmented by type, application, and region, along with in-depth insights into the leading companies and their market share. The report evaluates over 50 active players in the industry, with profiling of 9 major companies and an emphasis on Pfizer and Johnson & Johnson as market leaders. It includes data from more than 30 clinical trials, tracking product pipelines and stages of development across North America, Europe, Asia-Pacific, and the Middle East & Africa. Through its market segmentation section, the report breaks down data by type (diabetic and idiopathic gastroparesis) and by application (prokinetic agents, antiemetic agents, and others). It also analyzes drug formulations such as oral, injectable, and nasal sprays, providing a clear picture of where future growth is expected. Regionally, the report captures market performance across four primary regions. For example, North America continues to lead with a 45% share, while Asia-Pacific is projected to experience the fastest growth at 5.5% through 2029. The Europe and MEA regions are also evaluated based on prevalence data, infrastructure capacity, and regulatory environments. Additionally, the report includes 5 major developments from 2023–2024, providing up-to-date insights into R&D pipelines, mergers, partnerships, and FDA approvals. It analyzes ongoing investments—such as CinDome Pharma’s USD 40 million round—and discusses the implications of these activities for future market dynamics. Finally, the scope of the report extends to innovation tracking, with special emphasis on new product development. It includes 400 words on breakthrough drugs, formulation changes, and novel therapeutic classes, showcasing how industry leaders are tackling the clinical challenges of gastroparesis. These insights equip investors, healthcare professionals, and pharmaceutical companies with actionable information to navigate and leverage market opportunities.